Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer and keeping the price target at $28.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Terence Flynn has given his Hold rating due to a combination of factors tied to Pfizer’s execution, outlook, and valuation. The company modestly exceeded first‑quarter sales and earnings expectations and reaffirmed its 2026 guidance, including revenue, margin, and cost‑saving targets, while highlighting a path to high single‑digit annual revenue growth beyond 2028.
However, Flynn underscores that confidence in this longer‑term growth story hinges on successful commercial delivery and pipeline execution, particularly as COVID‑related products remain a drag in the near term and are skewed to the back half of the year. While legal outcomes and pipeline assets in areas such as metabolic disease, oncology, immunology, and vaccines support the strategic narrative, the risk‑reward appears balanced at current levels, leading him to maintain an Equal‑Weight stance with an unchanged $28 price target.
Flynn covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, BioNTech SE, and Biogen. According to TipRanks, Flynn has an average return of 9.8% and a 55.77% success rate on recommended stocks.